FDA rejects MAPS/Lykos MDMA therapy for PTSD
Send us a text On Aug 9th the FDA rejected the new drug application by Lykos (formerly MAPS PBC) for MDMA-assisted therapy for PTSD. This is disappointing news for those of us who were excited about the promising study results and eager to add MDMA-assisted therapy to the menu of treatment options for those suffering with PTSD. We discuss what appears to have influenced the FDA’s decision, the possible path forward for Lykos, how this ruling affects other companies trying to bring different p...